Last reviewed · How we verify
NCT06567418
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
trial testing alirocumab 75mg/2week in Acute Coronary Syndrome in 10,000 participants. Currently enrolling.
31 August 2024
Quick facts
| Lead sponsor | Yun Dai Chen |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 August 2024 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- alirocumab 75mg/2week — full drug profile →
- statin ± ezetimibe
Conditions studied
- Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
Sponsor
Yun Dai Chen — full company profile →
Who can join
18 and older, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ± ezetimibe on major cardiovascular events (MACE) in Chinese ACS patients. The main question it aims to answer is: whether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting. Data from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023. Patients diagnosed with STEMI, NSTEMI or UA at admission were identified at the first step. Then, for intervention group, patients who received alirocumab 75mg combined with statin ± ezetimibe during the ACS hospitalization (including the discharge date) will be included; for control group, patients who received statin ± ezetimibe during the ACS hospitalization will be included. All enrolled patients were required to have at least one documented follow-up visit.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06567418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
- NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
- NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting
Other Yun Dai Chen trials
Trials by the same sponsor.
- NCT06854523 — Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI) · NA · not yet recruiting
- NCT06738758 — Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of · recruiting
- NCT03413410 — A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute C · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06567418 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yun Dai Chen
- Last refreshed: 22 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing